Cigna’s stock leads selloff among drug middlemen on breakup fears — but this analyst says it’s not a real risk

One influential healthcare analyst says the chances of such a bill passing are less than 5%.

Cigna’s stock leads selloff among drug middlemen on breakup fears — but this analyst says it’s not a real risk
One influential healthcare analyst says the chances of such a bill passing are less than 5%.